Table 3 Treatment-related adverse events
|  | Grade 1–2 | Grade 3 | Grade 4 | Grade 5 |
|---|---|---|---|---|
Adverse event (n = 96) | ||||
Anemia | 16 (16.7) | 62 (64.6) | 2 (2.1) | 0 |
Neutropenia | 6 (6.3) | 60 (62.5) | 19 (19.8) | 0 |
Thrombocytopenia | 8 (8.3) | 14 (14.6) | 58 (60.4) | 0 |
Febrile neutropenia | 0 | 25 (26.0) | 10 (10.4) | 1 (1.0) |
Pneumonia | 1 (1.0) | 15 (15.6) | 6 (6.3) | 1 (1.0) |
Sepsis | 0 | 0 | 10 (10.4) | 1 (1.0) |
Nausea | 20 (22.9) | 3 (3.1) | 0 | 0 |
Constipation | 12 (12.5) | 0 | 0 | 0 |
Diarrhea | 11 (11.5) | 0 | 0 | 0 |
Vomiting | 10 (10.4) | 2 (2.1) | 0 | 0 |
Decreased appetite | 22 (22.9) | 2 (2.1) | 0 | 0 |
Hypokalemia | 13 (13.5) | 5 (5.2) | 1 (1.0) | 0 |
Peripheral edema | 10 (10.4) | 1 (1.0) | 0 | 0 |
Fatigue | 23 (24.0) | 2 (2.1) | 0 | 0 |
Mucositis | 8 (8.3) | 4 (4.2) | 0 | 0 |
Colitis | 5 (5.2) | 1 (1.0) | 0 | 0 |
Cough | 11 (11.5) | 1 (1.0) | 0 | 0 |
Muscle weakness | 0 | 1 (1.0) | 0 | 0 |
Hyperbilirubinemia | 9 (9.4) | 3 (3.1) | 0 | 0 |
ALT or AST elevation | 12 (12.5) | 4 (4.2) | 0 | 0 |
Allergic reaction | 3 (3.7) | 1 (1.0) | 0 | 0 |
Heart failure | 1 (1.0) | 2 (2.1) | 1 (1.0) | 1 (1.0) |
Renal failure | 0 | 0 | 1 (1.0) | 0 |
Tumor lysis syndrome | 0 | 1 (1.0) | 1 (1.0) | 0 |